MAPK3 and non-small cell lung carcinoma: This combination may also be effective in non-small cell lung cancer (NSCLC) and pancreatic tumours; however, we and others have noted more limited synergy between ERK1/2 pathway inhibitors and navitoclax/ABT-737 in melanoma11,26–28.